These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 23102599)

  • 1. Antibodies to malondialdehyde oxidized low-density lipoproteins predict long term cardiovascular mortality in high risk patients.
    Maiolino G; Pedon L; Cesari M; Frigo AC; Barisa M; Rossitto G; Seccia TM; Zanchetta M; Rossi GP
    Int J Cardiol; 2013 Sep; 168(1):484-9. PubMed ID: 23102599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between oxidized LDL, IgM, and IgG autoantibodies to ox-LDL levels with recurrent cardiovascular events in Swedish patients with previous myocardial infarction.
    Crisby M; Henareh L; Agewall S
    Angiology; 2014 Nov; 65(10):932-6. PubMed ID: 24288363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low levels of IgG autoantibodies against the apolipoprotein B antigen p210 increases the risk of cardiovascular death after carotid endarterectomy.
    Asciutto G; Dias NV; Edsfeldt A; Alm R; Fredrikson GN; Gonçalves I; Nilsson J
    Atherosclerosis; 2015 Apr; 239(2):289-94. PubMed ID: 25682025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies to oxidized low-density lipoproteins and angiographically assessed coronary artery disease in white patients.
    Rossi GP; Cesari M; De Toni R; Zanchetta M; Maiolino G; Pedon L; Ganzaroli C; Maiolino P; Pessina AC
    Circulation; 2003 Nov; 108(20):2467-72. PubMed ID: 14581399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events.
    Tsimikas S; Brilakis ES; Lennon RJ; Miller ER; Witztum JL; McConnell JP; Kornman KS; Berger PB
    J Lipid Res; 2007 Feb; 48(2):425-33. PubMed ID: 17093289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein.
    Tsimikas S; Lau HK; Han KR; Shortal B; Miller ER; Segev A; Curtiss LK; Witztum JL; Strauss BH
    Circulation; 2004 Jun; 109(25):3164-70. PubMed ID: 15184281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of cardiovascular risk in patients with rheumatoid arthritis: do cardiovascular biomarkers offer added predictive ability over established clinical risk scores?
    Finckh A; Courvoisier DS; Pagano S; Bas S; Chevallier-Ruggeri P; Hochstrasser D; Roux-Lombard P; Gabay C; Vuilleumier N
    Arthritis Care Res (Hoboken); 2012 Jun; 64(6):817-25. PubMed ID: 22302385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations among oxidized low-density lipoprotein antibody, C-reactive protein, interleukin-6, and circulating cell adhesion molecules in patients with unstable angina pectoris.
    Doo YC; Han SJ; Lee JH; Cho GY; Hong KS; Han KR; Lee NH; Oh DJ; Ryu KH; Rhim CY; Lee KH; Lee Y
    Am J Cardiol; 2004 Mar; 93(5):554-8. PubMed ID: 14996578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of MDA-LDL (malondialdehyde-modified low-density lipoprotein) as a prognostic marker for coronary artery disease in patients with type 2 diabetes mellitus.
    Kotani K; Tashiro J; Yamazaki K; Nakamura Y; Miyazaki A; Bujo H; Saito Y; Kanno T; Maekawa M
    Clin Chim Acta; 2015 Oct; 450():145-50. PubMed ID: 26265234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease Activity, Oxidized-LDL Fraction and Anti-Oxidized LDL Antibodies Influence Cardiovascular Risk in Rheumatoid Arthritis.
    Nowak B; Madej M; Łuczak A; Małecki R; Wiland P
    Adv Clin Exp Med; 2016; 25(1):43-50. PubMed ID: 26935497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoantibodies to oxidized low density lipoprotein: the relationship to low density lipoprotein fatty acid composition in diabetes.
    Griffin ME; McInerney D; Fraser A; Johnson AH; Collins PB; Owens D; Tomkin GH
    Diabet Med; 1997 Sep; 14(9):741-7. PubMed ID: 9300223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoantibodies to malondialdehyde-modified low-density lipoprotein in patients with angiographically confirmed coronary artery disease.
    McDowell A; Young IS; Wisdom GB
    J Pharm Pharmacol; 2002 Dec; 54(12):1651-7. PubMed ID: 12542895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma S100A8/A9 correlates with blood neutrophil counts, traditional risk factors, and cardiovascular disease in middle-aged healthy individuals.
    Cotoi OS; Dunér P; Ko N; Hedblad B; Nilsson J; Björkbacka H; Schiopu A
    Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):202-10. PubMed ID: 24202303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum malondialdehyde-modified low-density lipoprotein levels on admission predict prognosis in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Amioka N; Miyoshi T; Otsuka H; Yamada D; Takaishi A; Ueeda M; Hirohata S; Ito H
    J Cardiol; 2019 Sep; 74(3):258-266. PubMed ID: 30898480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-density lipoprotein particle number predicts coronary artery calcification in asymptomatic adults at intermediate risk of cardiovascular disease.
    Prado KB; Shugg S; Backstrand JR
    J Clin Lipidol; 2011; 5(5):408-13. PubMed ID: 21981843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The T(-786)C endothelial nitric oxide synthase genotype predicts cardiovascular mortality in high-risk patients.
    Rossi GP; Maiolino G; Zanchetta M; Sticchi D; Pedon L; Cesari M; Montemurro D; De Toni R; Zavattiero S; Pessina AC
    J Am Coll Cardiol; 2006 Sep; 48(6):1166-74. PubMed ID: 16979000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoantibody against, malondialdehyde-modified low density lipoprotein in patients with non-diabetic unstable angina: a potential role in immunologic reaction of plaque instability.
    Kwon KH; Kwon HM; Hong BK; Kim DS; Lee JY; Ryu SK; Park BE; Park HY; Kim JH; Yoon YW; Cho SY; Kim HS
    Yonsei Med J; 2002 Apr; 43(2):203-10. PubMed ID: 11971214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes.
    Tsimikas S; Bergmark C; Beyer RW; Patel R; Pattison J; Miller E; Juliano J; Witztum JL
    J Am Coll Cardiol; 2003 Feb; 41(3):360-70. PubMed ID: 12575961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein-associated phospholipase A2 activity predicts cardiovascular events in high risk coronary artery disease patients.
    Maiolino G; Pedon L; Cesari M; Frigo AC; Wolfert RL; Barisa M; Pagliani L; Rossitto G; Seccia TM; Zanchetta M; Rossi GP
    PLoS One; 2012; 7(10):e48171. PubMed ID: 23118945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OxPL/apoB, lipoprotein(a) and OxLDL biomarkers and cardiovascular disease in chronic hemodialysis patients.
    Bossola M; Tazza L; Luciani G; Tortorelli A; Tsimikas S
    J Nephrol; 2011; 24(5):581-8. PubMed ID: 21404224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.